MYGN: Myriad Genetics, Inc. - Summary | Jitta

Myriad Genetics, Inc.

NASDAQ:MYGN

Price
$13.30
Loss Chance
49.1%
3.51JITTA SCORE
1.75%Under Jitta Line
Jitta Ranking
143 / 902
2,151 / 4,264
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (27)
Recent Business Performance (9)
Financial Strength (73)
Return to Shareholders (19)
Competitive Advantage (34)
Jitta Signs
Debt LevelLow Long Term Debt
Revenue and EarningRevenue decline from 2017-2020
Operating MarginDeclined
Recent Business PerformanceEarning decline 1649.20% in the last quarter (yoy)
SG&A to SalesIncreasing
Key Stats
Jitta Score
Jitta Line
3.51
1.75%
1.50
162.75%
2.32
343.08%
Biotechnology
6.72
33.04%
7.12
51.07%
4.44
100.00%
COMPANY DESCRIPTION
Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice CDx, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.